Base de dados : LILACS
Pesquisa : D12.776.124.117 [Categoria DeCS]
Referências encontradas : 3 [refinar]
Mostrando: 1 .. 3   no formato [Detalhado]

página 1 de 1

  1 / 3 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1041441
Autor: Vernal, Sebastian; Brochado, Maria Jose Franco; Bueno-Filho, Roberto; Louzada-Junior, Paulo; Roselino, Ana Maria.
Título: Anti-phospholipid syndrome in seven leprosy patients with thrombotic events on corticosteroid and/or thalidomide regimen: insights on genetic and laboratory profiles
Fonte: Rev. Soc. Bras. Med. Trop;51(1):99-104, Jan.-Feb. 2018. tab, graf.
Idioma: en.
Resumo: Abstract INTRODUCTION Corticosteroids and/or thalidomides have been associated with thromboembolism events (TBE) in multibacillary (MB) leprosy. This report aimed to determine genetic and laboratory profiles associated with leprosy and TBE. METHODS Antiphospholipid antibodies (aPL), coagulation-related exams, prothrombin and Leiden's factor V mutations, and ß2-glycoprotein-I (ß2GPI) Val247Leu polymorphism were assessed. RESULTS Six out of seven patients with leprosy were treated with prednisone and/or thalidomide during TBE and presented at least one positive aPL. All patients presented ß2GPI polymorphism, and one showed prothrombin mutation. CONCLUSIONS Corticosteroid or thalidomide adverse effects and aPL and ß2GPI polymorphisms may cause TBE in patients with MB leprosy.
Descritores: Talidomida/administração & dosagem
Síndrome Antifosfolipídica/genética
Síndrome Antifosfolipídica/tratamento farmacológico
Síndrome Antifosfolipídica/sangue
Corticosteroides/administração & dosagem
Hanseníase Multibacilar/imunologia
-Polimorfismo Genético
Talidomida/efeitos adversos
Fator V/análise
Imunoglobulina G/sangue
Imunoglobulina M/sangue
Protrombina/análise
Ensaio de Imunoadsorção Enzimática
Anticorpos Antifosfolipídeos/efeitos dos fármacos
Anticorpos Antifosfolipídeos/genética
Anticorpos Antifosfolipídeos/sangue
Corticosteroides/efeitos adversos
beta 2-Glicoproteína I/sangue
Tromboembolia Venosa/tratamento farmacológico
Hanseníase Multibacilar/genética
Hanseníase Multibacilar/tratamento farmacológico
Pessoa de Meia-Idade
Mutação
Limites: Humanos
Masculino
Feminino
Adolescente
Idoso
Responsável: BR1.1 - BIREME


  2 / 3 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1088611
Autor: Ribeiro, Sandra Lúcia Euzébio; Pereira, Helena Lúcia Alves; Boechat, Antonio Luiz; Silva, Neusa Pereira; Sato, Emilia Ionue; Cunha, Maria das Graças Souza; Passos, Luiz Fernando de Souza; Dos-Santos, Maria Cristina.
Título: Epidemiological, clinical and immune factors that influence the persistence of antiphospholipid antibodies in leprosy
Fonte: Adv Rheumatol;59:52, 2019. tab, graf.
Idioma: en.
Resumo: Abstract Introduction: Antiphospholipid antibodies (aPL) are described in individuals with leprosy without the clinical features of antiphospholipid antibody syndrome (APS), a condition involving thromboembolic phenomena. We have described the persistence of these antibodies for over 5 years in patients with leprosy after specific treatment. Objectives: To determine whether epidemiological, clinical and immunological factors played a role in the longterm persistence of aPL antibodies in leprosy patients after multidrug therapy (MDT) had finished. Methods: The study sample consisted of 38 patients with a diagnosis of leprosy being followed up at the Dermatology and Venereology Outpatient Department at the Alfredo da Matta Foundation (FUAM) in Manaus, AM. ELISA was used to detect anticardiolipin (aCL) and anti-β2 glycoprotein I (anti-β2GPI) antibodies. Patients were reassessed on average of 5 years after specific treatment for the disease (MDT) had been completed. Results: Persistence of aPL antibodies among the 38 leprosy patients was 84% (32/38), and all had the IgM isotype. Mean age was 48.1 ± 15.9 years, and 23 (72.0%) were male. The lepromatous form (LL) of leprosy was the most common (n = 16, 50%). Reactional episodes were observed in three patients (9.4%). Eighteen (47.37%) were still taking medication (prednisone and/or thalidomide). Mean IgM levels were 64 U/mL for aCL and 62 U/mL for anti-β2GPI. In the multivariate binary logistic regression the following variables showed a significant association: age (p = 0.045, OR = 0.91 and CI 95% 0.82-0.98), LL clinical presention (p = 0.034; OR = 0.02 and CI 95% = 0.0-0.76) and bacterial index (p = 0.044; OR = 2.74 and CI 95% = 1.03-7.33). We did not find association between prednisone or thalidomide doses and positivity for aPL (p = 0.504 and p = 0.670, respectively). No differences in the variables vascular thrombosis, pregnancy morbidity, diabetes, smoking and alcoholism were found between aPL-positive and aPL-negative patients. Conclusion: Persistence of positivity for aPL antibodies was influenced by age, clinical presentation and bacterial index. However, further studies are needed to elucidate the reason for this persistence, the role played by aPL antibodies in the disease and the B cell lineages responsible for generation of these antibodies.
Descritores: Hanseníase/patologia
-Ensaio de Imunoadsorção Enzimática/instrumentação
Anticorpos Antifosfolipídeos/análise
Anticorpos Anticardiolipina/análise
Quimioterapia Combinada/efeitos adversos
beta 2-Glicoproteína I/análise
Limites: Humanos
Responsável: BR1.1 - BIREME


  3 / 3 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1143628
Autor: Funke, Andreas; Staub, Henrique Luiz; Monticielo, Odirlei Andre; Balbi, Gustavo Guimarães Moreira; Danowski, Adriana; Santiago, Mittermayer Barreto; Andrade, Danieli Castro Oliveira de; Rêgo, Jozelia.
Título: Non-criteria Antiphospholipid Antibodies: a narrative review
Fonte: Rev. Assoc. Med. Bras. (1992);66(11):1595-1601, Nov. 2020. tab.
Idioma: en.
Resumo: SUMMARY The 2006 Revised Sapporo Classification Criteria for Definite Antiphospholipid Syndrome included as laboratory criteria the tests for antiphospholipid antibodies whose accuracy was regarded as satisfactory according to the evidence available at that time. In practice, however, the sensitivity and specificity of these "criteria" of antiphospholipid antibodies are sometimes insufficient for identifying or ruling out antiphospholipid syndrome. It has been studied whether the accuracy of the laboratory diagnosis of the syndrome could be improved by testing for non-criteria antiphospholipid antibodies. In this work, we review evidence on the clinical associations and diagnostic value of the most commonly studied non-criteria antibodies, namely: antiphosphatidylethanolamine, anti-annexin A5, anti-prothrombin, anti-phosphatidylserine/prothrombin complex, IgA anticardiolipin, and IgG anti-domain I of the β2 glycoprotein antibodies.

RESUMO A classificação de Sapporo revisada para a síndrome antifosfolipídica definida de 2006 incluiu como critérios laboratoriais aqueles testes para anticorpos antifosfolípides cuja acurácia era considerada satisfatória de acordo com a evidência então disponível. Porém, na prática, a sensibilidade e especificidade desses anticorpos antifosfolípides "critério" são por vezes insuficientes para identificar ou descartar a síndrome antifosfolípide. Tem-se estudado se a acurácia do diagnóstico laboratorial da síndrome poderia ser melhorada por meio da testagem de anticorpos antifosfolípides não critério. Neste trabalho revisamos a evidência a respeito das associações clínicas e valor diagnóstico dos anticorpos não critério mais estudados, nomeadamente: anticorpos antifosfatidiletanolamina, antianexina A5, antiprotrombina, anticomplexo fosfatidilserina/protrombina, IgA anticardiolipina e IgG antidomínio I da anti-β2 glicoproteína I.
Descritores: Síndrome Antifosfolipídica/diagnóstico
-Protrombina
Sensibilidade e Especificidade
Anticorpos Antifosfolipídeos
Anticorpos Anticardiolipina
beta 2-Glicoproteína I
Limites: Humanos
Tipo de Publ: Revisão
Responsável: BR1.1 - BIREME



página 1 de 1
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde